Moderna reported fourth quarter 2025 revenue of $700 million and full-year revenue of $1.9 billion, driven primarily by Spikevax and the successful U.S. launch of MNEXT Spike. The company achieved significant operational discipline, reducing operating expenses by 30% ($2.2 billion) year-over-year, which helped narrow the net loss to $2.8 billion ($7.26 per share) for the full year. Despite these losses, Moderna ended 2025 with a strong cash position of $8.1 billion, bolstered by cost control and a $600 million credit facility draw. Looking ahead to 2026, management projects revenue growth of up to 10%, fueled by international partnerships in the U.K., Canada, and Australia, and the continued uptake of MNEXT Spike. The pipeline remains robust with key data readouts expected for the INT oncology program and norovirus vaccine, though the FDA's refusal to file for the seasonal flu vaccine mRNA-1010 presents a notable regulatory headwind in the U.S.
| Metric | Value | Change |
|---|---|---|
| Q4 2025 Revenue | $700,000,000 | N/A |
| FY 2025 Total Revenue | $1,900,000,000 | N/A |
| FY 2025 Net Loss | $2,800,000,000 | Improved from $3.6B loss in 2024 |
| FY 2025 Loss Per Share | $7.26 | Improved from $9.28 in 2024 |
| Cash & Investments | $8,100,000,000 | Decreased from $9.5B at end of 2024 |
| Operating Expenses Reduction | 30% | Down $2.2B |
| MNEXT Spike US Retail Market Share | 24% | N/A (New Product) |
Moderna is executing a strategic pivot towards international growth, leveraging local manufacturing partnerships in the U.K., Canada, and Australia to drive revenue. Management highlighted that these agreements, which include domestic manufacturing and R&D commitments, are core to national security strategies. This shift is critical as it diversifies revenue away from the volatile U.S. market and positions the company for the 2027 opening of the European respiratory market, where they were previously excluded by a competitor's pandemic contract.
The company's oncology pipeline, specifically the INT program developed with Merck, is reaching a critical maturity phase with three fully enrolled late-stage studies across melanoma, renal cell carcinoma, and bladder cancer. Management emphasized the durability of the five-year melanoma data, reinforcing their confidence in the program's long-term potential. This signals a transition from a pure-play vaccine company to a diversified immunotherapy player, which is essential for long-term value creation as COVID revenues decline.
Financial discipline has emerged as a core strategic pillar, with the company reducing operating expenses by $2.2 billion (30%) in 2025. Management noted that AI tools have been adopted across the business to drive productivity. This aggressive cost management, combined with better-than-expected working capital performance, has extended the cash runway to $8.1 billion, providing the necessary capital to fund late-stage trials through 2026 without immediate dilution.
Moderna is advancing a multi-pronged respiratory strategy despite the U.S. flu setback. The company is pushing forward with its Flu/COVID combination vaccine (mRNA-1083) in Europe and Canada, with potential approvals in 2026. Additionally, the successful launch of MNEXT Spike, which captured 24% of the U.S. retail market, demonstrates their ability to compete on product profile (efficacy) rather than just pandemic necessity, setting the stage for share gains in international markets.
The FDA issued a Refusal to File (RTF) letter for the seasonal flu vaccine mRNA-1010, a major regulatory setback. Management expressed disappointment and noted that the 'uncertainty in the U.S. FDA regulatory environment creates real challenges.' This delays U.S. market entry for a key product, complicates the path for the combination flu/COVID vaccine, and threatens the company's previous guidance of achieving cash flow breakeven by 2028.
The company continues to burn significant cash, reporting a net loss of $2.8 billion for the year. While cost controls are in place, the guidance for 2026 ending cash ($5.5B-$6.0B) implies continued substantial burn. The reliance on a declining COVID market—where management acknowledges 'future potential declines in COVID vaccination rates'—creates a revenue gap that new products must quickly fill to avoid further liquidity deterioration.
Management provided vague timelines for key catalysts, particularly regarding the INT melanoma data and the resolution of the FDA flu issue. When pressed on the Type A meeting timeline and the implications for 2028 goals, CFO James Mock stated, 'it is a little bit too early to tell.' This lack of visibility, combined with 'event-driven' trials, makes it difficult for investors to model the path to profitability with precision.
There is a notable competitive risk in Europe, where management admitted Moderna has been 'excluded from this region for several years due to a competitor pandemic contract.' While this expires in 2026, re-entering a market where competitors have established footprints requires heavy commercial investment. Furthermore, the U.S. flu refusal highlights a vulnerability where regulatory hurdles may prevent Moderna from competing effectively against established flu players.
Overall: Management exhibited a tone of disciplined resilience mixed with clear frustration regarding U.S. regulatory affairs. Stéphane Bancel was notably critical of the FDA's unpredictability regarding the flu vaccine but expressed strong pride in the team's cost-cutting execution. Stephen Hoge remained scientifically optimistic, emphasizing the strength of clinical data and international opportunities, while James Mock focused on financial prudence and exceeding cash guidance.
Confidence: MEDIUM - Management is confident in its financial restructuring and pipeline execution (oncology, international expansion), but confidence is clearly tempered by the significant regulatory setback with the FDA on the flu vaccine and the inherent decline of the COVID market.
Up to 10% growth
Approximately $3,000,000,000
$1,000,000,000 (flat)
$5.5 to $6.0 billion
Approximately $900,000,000
Hedging & Uncertainty: Management employed frequent hedging language, particularly regarding the U.S. regulatory path and specific financial targets. Phrases like 'up to 10% revenue growth,' 'potential declines,' and 'it is a little bit too early to tell' were used to manage expectations. Stephen Hoge hedged on the flu timeline, stating, 'until we have that Type A meeting, we will not really know how quickly we can get moving forward.' This pattern of uncertainty suggests that while the pipeline is robust, external factors (regulators, market dynamics) introduce significant variability to their outlook.
The current uncertainty in the U.S. FDA regulatory environment creates real challenges for businesses, patients, and the broader innovation ecosystem. - Stéphane Bancel, CEO
We expect total revenue growth of up to 10% in 2026. - James Mock, CFO
We were disappointed with the FDA’s refusal to file letter for mRNA-1010... - Stephen Hoge, President
It is a little bit too early to tell. - James Mock, CFO
We look forward to the data readout from these studies. - Stéphane Bancel, CEO
We have a ton of momentum from a cost perspective. - James Mock, CFO
Analyst Sentiment: Analysts were highly focused on the implications of the FDA's refusal to file for the flu vaccine, specifically asking about the timeline for the Type A meeting, the impact on the 2028 breakeven guidance, and the read-through to the combination vaccine. There was also significant interest in the timing of the INT melanoma data and the mechanics of the European market expansion.
Management Responses: Management was transparent about the lack of visibility regarding the FDA, repeatedly deferring specific timeline questions until after the Type A meeting occurs. They were more confident and specific when discussing oncology data and the financial mechanics of the cash balance, though they maintained a cautious 'event-driven' stance on clinical trial readouts.
The impact of the FDA Refusal to File (RTF) for mRNA-1010 and the timeline for resolution via a Type A meeting.
The specific timing of the Phase 3 INT adjuvant melanoma data readout (interim vs. final) and the probability of success across different histologies.
The dynamics of the European respiratory market, including pricing, vaccination rates, and the competitive landscape post-2026.
The breakdown of the better-than-expected cash balance, specifically regarding working capital management and cost discipline.
Moderna remains in a complex transition phase. The company successfully executed a massive financial restructuring, beating cost-cutting targets and preserving a strong cash balance of $8.1 billion. The pipeline, particularly the INT oncology partnership with Merck and the norovirus program, offers significant long-term upside. However, the investment thesis faces a serious near-term headwind: the FDA's refusal to file for the seasonal flu vaccine. This regulatory rejection not only delays a key revenue driver but also introduces uncertainty regarding the combination flu/COVID vaccine and the company's ability to reach cash flow breakeven by 2028. While international expansion and MNEXT Spike provide growth avenues, the current U.S. regulatory environment and declining COVID revenues suggest that the stock is likely to remain range-bound until clearer catalysts emerge from the oncology pipeline or the flu situation is resolved.
Management highlighted a deteriorating and unpredictable U.S. FDA regulatory environment, specifically contrasting it with smoother paths in Europe and Canada. They noted that 'uncertainty in the U.S. FDA regulatory environment creates real challenges' and threatens U.S. leadership in innovation.
There is a sustained global focus on pandemic preparedness, evidenced by new strategic agreements with Mexico and Taiwan. These government partnerships, focused on domestic supply security, are providing a stable revenue floor outside of the commercial market.
Management noted that the European COVID market is currently distorted by pandemic contracts with competitors, but these are set to expire in 2026. This suggests a normalization of the market and a leveling of the playing field for Moderna's entry in 2027.